DRUG INFORMATION ON ZOHYDRO ER
GENERIC NAME:Hydrocodone Bitartrate Extended relese Capsule
BRAND NAME: ZOHYDRO ER
APPROVED DATE: 25 October 2013
MARKETED COMPANY: Zogenixinc.,
INDICATION:Chronic pain management
MECHANISM OF ACTION:
Hydrocodone is a semi-synthetic opioid agonist with relative selectivity for the mu-opioid
receptor, although it can interact with other opioid receptors at higher doses.
Hydrocodone acts as a full agonist, binding to and activating opioid receptors at sites in
the peri-aquaductal and peri-ventricular gray matter, the ventro-medial medulla and the
spinal cord to produce analgesia. The analgesia, as well as the euphorant, respiratory
depressant and physiologic dependence properties of μ agonist opioids like hydrocodone,
result principally from agonist action at the μ receptors
Zohydro ER capsules exhibit peak plasma concentrations occurring approximately 5
hours after dose administration was administered with a high-fat meal.
Although the extent of protein binding of hydrocodone in human plasma has not been
definitely determined, structural similarities to related opioid analgesics suggest that
hydrocodone is not extensively protein bound. As most agents in the 5-ring
morphinangroup of semi-synthetic opioids bind plasma protein to a similar degree range
19% [hydromorphone]to 45% [oxycodone]), hydrocodone is expected to fall within this
Hydrocodone exhibits a complex pattern of metabolism, including N-demethylation, Odemethylation, and 6-keto reduction to the corresponding 6-α-and 6-β-hydroxy
metabolites. CYP3A4 mediated N-demethylation to norhydrocodone is the primary
metabolic pathway of hydrocodone with a lower contribution from CYP2D6 mediated Odemethylation to hydromorphone. Hydromorphone is formed from the O-demethylation
of hydrocodone and may contribute to the total analgesic effect of hydrocodone.
Hydrocodone and its metabolites are eliminated primarily in the kidneys, with a mean
apparent plasma half-life after Zohydro ER administration of approximately 8 hours.
Central Nervous System
The principal therapeutic action of hydrocodone is analgesia. In common with other
opioids, hydrocodone causes respiratory depression, in part by a direct effect on the
brainstem respiratory centers. The respiratory depression involves a reduction in the
responsiveness of the brain stem respiratory centers to both increases in carbon dioxide
tension and electrical stimulation. Opioids depress the cough reflex by direct effect on
the cough center in the medulla.
Hydrocodone causes miosis, even in total darkness. Pinpoint pupils are a sign of opioid
overdose but are not pathognomonic.
Gastrointestinal Tract and Other Smooth Muscle
Hydrocodone causes a reduction in motility associated with an increase in smooth muscle
tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine
is delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the
colon are decreased, while tone may be increased to the point of spasm resulting in
constipation. Other opioid-induced effects may include a reduction in gastric, biliary and
pancreatic secretions, spasm of sphincter of Oddi, and transient elevations in serum
Hydrocodone may produce release of histamine with or without associated peripheral
vasodilation. Manifestations of histamine release and/or peripheral vasodilation may
include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.
The recommended dose is a 200 mg subcutaneous injection at Week 0, followed by 100
mg at Week 2 and then maintenance therapy with 100 mg every 4 weeks.
Extended Relese Capsule
acute or severe bronchial asthma or hypercarbia
hypersensitivity to any components of Zohydro ER or the active ingredient, hydrocodone
ADVERSE DRUG REACTION:
Dry m outh
Upper respiratory tract infection
Urinary tract infection
Back pain and tremor.
DRUG -DRUG INTERACTION:
CNS depressants: Increased risk of respiratory depression, hypotension, profound
sedation, coma or death. When combined therapy with CNS depressant is contemplated,
the dose of one or both agents should be reduced
Mixed Agonists/Antagonists: May precipitate withdrawal or decrease analgesic effect if
given concurrently with Zohydro ER.
The use of MAO inhibitors or tricyclic antidepressants with Zohydro ER may increase
the effect of either the antidepressant or Zohydro ER.
Misuse, abuse, and diversion: Zohydro ER is an opioid agonist and a Schedule II
controlled substance with a high potential for abuse similar to fentanyl, methadone,
morphine, oxycodone, and oxymorphone.
Interactions with CNS depressants: Concomitant use may cause profound sedation,
respiratory depression, and death. If coadministration is required, consider dose reduction
of one or both drugs.
Elderly, cachectic, debilitated patients, and those with chronic pulmonary disease:
Monitor closely because of increased risk for life-threatening respiratory depression.
Patients with head injury or increased intracranial pressure: Monitor for sedation and
respiratory depression. Avoid use of Zohydro ER in patients with impaired consciousness
or coma susceptible to intracranial effects of CO2 retention.
Prolonged gastric obstruction: May occur in patients with gastrointestinal obstruction.
Concomitant use of CYP3A4 inhibitors may increase opioid effects.
Impaired mental/physical abilities: Caution must be used with potentially hazardous
Store at 25° C (77° F); excursions permitted to 15°–30° C (59°–86° F)
FDA APPROVED DRUG 2013